National Cancer Institute, Naples
istitutotumori.na.itLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
113
Active
36
Phase 3
23
Total enrollment
63,946
Pipeline matrix
Showing 32 of 32 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Panitumumab | — | — | — | — | 4 | ||
| Irinotecan | — | — | — | — | 2 | ||
| 5-fluorouracil | — | — | — | — | 6 | ||
| Olaparib | — | — | — | — | 2 | ||
| Chemotherapy drug | — | — | — | — | — | 1 | |
| L-folinic acid | — | — | — | — | — | 1 | |
| Valproic Acid | — | — | — | — | — | 5 | |
| cisplatin | — | — | — | — | 10 | ||
| Capecitabine | — | — | — | — | 7 | ||
| Pembrolizumab | — | — | — | — | — | 2 | |
| Regorafenib | — | — | — | — | — | 2 | |
| standard nivolumab and oxaliplatin- based chemotherapy | — | — | — | — | — | 1 | |
| simvastatin in combination with standard nivolumab and oxaliplatin-based chemotherapy | — | — | — | — | — | 1 | |
| Folfiri/Cetuximab | — | — | — | — | — | 1 | |
| Cannabis Extract Oil | — | — | — | — | — | 1 | |
| Inavolisib | — | — | — | — | — | 1 | |
| Cabozantinib and Temozolomide | — | — | — | — | — | 1 | |
| Lenvatinib | — | — | — | — | — | 1 | |
| Durvalumab 1120 mg | — | — | — | — | — | 1 | |
| Durvalumab 1500 mg | — | — | — | — | — | 1 | |
| Tremelimumab i.v. at 300 mg | — | — | — | — | — | 1 | |
| Cisplatin (CDDP) 25 mg/mq i.v | — | — | — | — | — | 1 | |
| Gemcitabine (GEM) 1000 mg/mq i.v. | — | — | — | — | — | 1 | |
| standard second line treatment, at discretion of the investigator | — | — | — | — | — | 1 | |
| Combined Androgen Deprivation Therapy with Relugolix and Image-Guided Stereotactic Body Radiotherapy | — | — | — | — | — | 1 | |
| Simvastatin 20mg | — | — | — | — | — | 1 | |
| Gemcitabine 1000 mg | — | — | — | — | — | 1 | |
| Nab paclitaxel | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | 2 | ||
| Peptide-based hepatocellular carcinoma vaccine IMA970A | — | — | — | — | — | 1 | |
| [68Ga]Ga-R54 PET/CT | — | — | — | — | — | 1 | |
| Dostarlimab | — | — | — | — | — | 1 |
Next readouts
- 2023-05-19
- 2025-01
- 2025-08-28
- 2025-09
- 2026-08
- 2026-10
- 2026-12-20
- 2027-01
- 2027-01
- 2027-05-31
Top conditions
- Ovarian Cancer12
- Breast Cancer9
- Endometrial Cancer5
- Colorectal Cancer5
- Metastatic Colorectal Cancer4
- Colorectal Cancer Stage IV3
- Cancer3
- Hepatocellular Carcinoma3
Frequently asked questions about National Cancer Institute, Naples
- How many clinical trials does National Cancer Institute, Naples have on ClinicalTrials.gov?
- National Cancer Institute, Naples is listed as the lead sponsor on 113 clinical trials in ClinicalTrials.gov, 36 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Cancer Institute, Naples's trials are in Phase 3?
- 23 of National Cancer Institute, Naples's trials are in Phase 3, spread across 32 active drug programs.
- What therapeutic areas does National Cancer Institute, Naples focus on?
- National Cancer Institute, Naples's most-studied conditions on ClinicalTrials.gov are Ovarian Cancer, Breast Cancer, Endometrial Cancer, Colorectal Cancer, Metastatic Colorectal Cancer.
- When are National Cancer Institute, Naples's next clinical trial readouts?
- National Cancer Institute, Naples has 10 upcoming primary-completion readouts tracked here; the soonest is “Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients”, expected around 2023-05-19.